Kiniksa Pharmaceuticals Ltd. (KNSA)
| Market Cap | 968.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -184.45M |
| Shares Out | 32.32M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $14.50 |
| Previous Close | $14.15 |
| Change ($) | 0.35 |
| Change (%) | 2.47% |
| Day's Open | 14.23 |
| Day's Range | 14.08 - 14.62 |
| Day's Volume | 660,529 |
| 52-Week Range | 13.00 - 24.70 |
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 ...
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological p...
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications -
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tu...
- ARCALYST ® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - - Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation ...
- Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data - - 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH chall...
– P rimary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined st...
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis – - ARCALYST now available on prescription basis in the U.S. – - Kiniksa One Connect™ program provides ongoing patient ac...
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - - Commercial launch expected in April 2021 - - Kiniksa launches Kiniksa One Connect™ patient support program - - Confer...
- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date ...
HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan...
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab –
– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously – – Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –
- R eceptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –
HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, De...
- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY , which achieved its primary and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to Kiniksa fro...
Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased sustained remission Primary and secondary efficacy endpoints achieved statist...
HAMILTON, Bermuda, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological p...
Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020 Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of...
- Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statistical signi...
- Primary and secondary efficacy endpoints statistically significant - - Primary and secondary efficacy endpoints statistically significant -
- Virtual e vent to take place from 8:00 a.m. to 9: 3 0 a.m. E D T -
- Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT- - Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT-
HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conferenc...
HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercia...
HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, A...
– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –
HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A c...
HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0 million...
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercia...
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
HAMILTON, Bermuda, June 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commerciali...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma
HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commerciali...
HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializ...
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Cla...
HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 of its Cla...
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier weani...
As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 - - Statistically significant secondary efficacy endpoint of imp...
Kiniksa announced an unexpected move into the COVID-19 furore.
Is (KNSA) Outperforming Other Medical Stocks This Year?
- All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Consortium of U.S. academic site...
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the pivota...
These three clinical-stage biotechs could all double in value before year's end.
Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta
About KNSA
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixa... [Read more...]
| Industry Biotechnology | IPO Date May 24, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol KNSA |
Analyst Forecasts
According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is 32.00, which is an increase of 120.69% from the latest price.